Invests in categories: BioTechDevelopmentDrugHealthcareHealthTechMedtechPlatformProductResearchTherapeutics
Impacting the future of medicine.
News
365
Portfolio
99
Persons
21
Mentions
211
Employees: 11-50
Investment Stage: Seed; Series A; Series B; Series C; Series D
Portfolio 99
Show more
Persons 21
| Date | First Name | Last Name | Title | Location | |||
| - | Felix | Güttersber... | Analyst | - | - | - | |
| - | Cyril | Lesser, MS... | Vice Presi... | - | - | - | |
| - | Sharon | Dirkse | Office Man... | - | - | - | |
| - | Floor | Saris, MSc | Advisor | - | - | - | |
| - | Iris | Veldman, L... | Deal Couns... | - | - | - | |
| - | Carlo | Incerti, M... | Operating ... | - | - | - | |
| - | Daniel | Bode, PhD | Senior Ana... | - | - | - | |
| - | Felix | Güttersber... | Analyst | - | - | - | |
| - | Alice | Vickers, P... | - | - | - | - | |
| - | Charlotte | Koldeweij,... | Fellow | - | - | - | |
| - | Alexander | Hoffmann | General Pa... | - | - | - | |
| - | Antoine | Boulanger,... | Principal | - | - | - | |
| - | Chelle | Tjabring | Senior Exe... | - | - | - | |
| - | Devan | Sequeira, ... | IT Solutio... | - | - | - | |
| - | Feike | Sijbesma | Senior Adv... | - | - | - | |
| - | Danielle | de Magalhã... | Executive ... | - | - | - | |
| - | Cees | de Jong, M... | Venture Pa... | - | - | - | |
| - | Devan | Sequeira ,... | IT Solutio... | - | - | - | |
| - | Audrey | Cacaly, MS... | Principal | - | - | - | |
| - | Elisa | Camorani, ... | Senior Ass... | - | - | - | |
| - | Alicia | Dortona | Office Man... | - | - | - |
Show more
News 365
| Date | Title | Description |
| 05.09.2025 | Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression | - Treatment with pridopidine slowed clinical progression and maintained function, cognition, and motor performance in pre-defined analyses of a subgroup of early-stage Huntington’s disease (HD) patients who were not taking antidopaminergic ... |
| 02.09.2025 | First Patient Dosed in Citryll's Phase IIA Trial Evaluating CIT-013 i Rheumatoid Arthritis | - Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 – Citryll, a biotech company pioneering a trans... |
| 26.08.2025 | Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis | - CAL101 is a first-in-class monoclonal antibody targeting S100A4, a damage-associated molecular pattern (DAMP) protein associated with serious and life-threatening fibrotic disorders - Phase 2 AURORA study of CAL101 designed to prevent lun... |
| 12.08.2025 | AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease | MILAN, August 12, 2025 — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has gr... |
| 05.08.2025 | SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline | Top-Line Results from Study Evaluating Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) Expected in First Quarter of 2026 DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited... |
| 30.07.2025 | NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025 | -- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CE... |
| 28.07.2025 | Forbion Co-Leads $372.5 Million Series D Financing in MapLight Therapeutics | • One of the largest private biotech financings of 2025, following Forbion-backed Verdiva • MapLight Therapeutics is the sixth private investment made from the Forbion Growth III Fund Naarden, The Netherlands, July 28, 2025 – Forbion, a lea... |
| 28.07.2025 | Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively | • First patient dosed in global pivotal clinical trial program for late infantile/juvenile onset NPC and GM1/GM2 gangliosidoses. • Both studies are part of Azafaros’ mission to develop treatments for the unmet need of patients with rare lys... |
| 25.07.2025 | Citryll Announces Formation Of Scientific Advisory Board | Board comprises world-renowned experts in biology, immunology and pathology. Oss, Netherlands – 24 July 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Ne... |
| 25.07.2025 | Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease | NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain--(BUSINESS WIRE)-- Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has r... |
| 15.07.2025 | AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial | - AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutation - CELESTE is informed by the STELLA prospective natural history study, which is cur... |
| 08.07.2025 | Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP | LONDON and CAMBRIDGE, Mass., July 8, 2025 – Beacon Therapeutics Holdings Limited (“Beacon Therapeutics” or ”the Company”), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blindin... |
| 30.06.2025 | Forbion Announces Fifth Exit from Forbion Growth Opportunities Fund II with the Sale of Capstan Therapeutics to AbbVie for USD 2.1 Billion | • Capstan sale ranks as the largest ever payment for an early-stage private biotech company by upfront consideration value and is Forbion’s seventh consecutive >$1B exit. • Capstan’s in vivo CAR-T platform offers a first-in-class approac... |
| 25.06.2025 | FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer | BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerati... |
| 25.06.2025 | Vor Bio Announces $175 Million Private Placement | June 25, 2025 CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchas... |
| 11.06.2025 | Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease | - CPTX2309 is a targeted lipid nanoparticle that delivers an anti-CD19 CAR mRNA preferentially to CD8-expressing cytotoxic T cells - mRNA-based approach is designed to achieve rapid, deep, and transient B cell depletion without the need for... |
| 09.06.2025 | Forbion co-leads $80 Million Series A Financing in Mosanna Therapeutics to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea | Naarden, The Netherlands – June 9, 2025 – Forbion, a leading venture capital firm with deep biotech expertise in Europe and the US announces that it has co-led an $80 Million Series A financing in Mosanna Therapeutics, a biotech company ret... |
| 03.06.2025 | Orbis Medicines Accelerates Next-Generation Oral Macrocycle Platform with Enhanced Artificial Intelligence Capabilities of Gefion Supercomputer | - Orbis begins using Gefion, Denmark’s first AI supercomputer - Composed of 1,528 NVIDIA H100 Tensor Core GPUs, system is optimized for large-scale, AI-driven projects - Enables significant expansion of macrocycle chemical space exploration... |
| 19.05.2025 | Forbion co-leads $120 million investment in CellCentric to advance inobrodib for treating multiple myeloma | • Funding to support late stage development of a novel oral p300/CBP inhibitor, inobrodib for the treatment of multiple myeloma • As part of its global team expansion, the company opened a new office just outside Boston in Burlington, MA • ... |
| 13.05.2025 | Forbion co-leads € 132M Series B Oversubscribed Financing in Azafaros to Advance Phase 3 Clinical programs of innovative therapies in lysosomal storage disorders | • Financing round led by Jeito Capital and co-led by Forbion Growth, with participation from Seroba, Pictet Group and other existing investors • Proceeds to fund two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick di... |
| 12.05.2025 | Bio€quity Europe 2025 | The 25th Bio€quity Europe takes place at the Bruges Meeting & Convention Centre (BMCC) from 12 - 14 May 2025. On 13 May, Managing Partner Dirk Kersten will take part in the session "Growth Capital: Essential Pillars for the Europea... |
| 15.04.2025 | The 2025 Cell & Gene Meeting on the Med | The 2025 Cell & Gene Meeting on the Med 15 - 17 April, Rome, Italy The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the ATMP community from Europe and beyond. Forbion Senior Associate Tim Loho... |
| 08.04.2025 | Invest Europe: Sustainability in a changing geopolitical landscape: what you need to know | Forbion Head of Impact and ESG will be a panelist for the Invest Europe webinar "Sustainability in a changing geopolitical landscape: what you need to know." The panel will explore: Navigating increasing policy uncertainty in PE, ... |
| 03.03.2025 | Forbion Expands US Presence with the Appointment of Regina Salvat, PhD, as Principal in the Boston Office | Naarden, The Netherlands - 03 March 2025 - Forbion is pleased to announce the appointment of Regina Salvat, PhD, as Principal in our Boston office. This strategic hire underscores our commitment to strengthening our presence in the United S... |
| 23.02.2025 | 18th Annual European Life Sciences CEO Forum | The 18th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. The main programme for the 18th Annual ELSF is spread over 2 days (26th - 27th of Februar... |
| 18.02.2025 | LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors | • Dr Mozayeni brings deep experience in biotech corporate strategy and business development • Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors to treat Huntington’s disease into th... |
| 11.02.2025 | Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors | - Tosh, formerly President of Idorsia and Chief Operating Officer of ChemoCentryx, brings more than 20 years of leadership experience from global pharma and biotech companies - Khurem Farooq, Chief Executive Officer of Verdiva Bio and forme... |
| 28.01.2025 | IPEM | Since 2016, IPEM Cannes has brought a different essence to the private capital industry by gathering its key decision-makers in a conducive environment for meaningful exchanges. With its vibrant ecosystem, IPEM Cannes and the brand-new even... |
| 27.01.2025 | Forbion BioEconomy Fund I surpasses €150 million target, raising €164.5 million with strong institutional LP support | • Forbion’s BioEconomy Fund I has raised €164.5 million to date, exceeding its €150 million target in just over a year, since launching in November 2023. • Institutional investors, include KfW Capital, Novo Holdings, Rentenbank, Aurae Impac... |
| 13.01.2025 | Forbion promotes Dirk Kersten to Managing Partner and strengthens US team | • Dirk Kersten promoted to Managing Partner, further strengthening firm’s leadership • Jonathan McNeill, M.D. joins Forbion as Partner in the Boston office Naarden, The Netherlands – 13 January 2025 - Forbion, a leading global life sciences... |
| 09.01.2025 | CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab | Munich, Germany and San Francisco, USA, January 09, 2025 – CatalYm today announced the appointment of Scott Clarke as Chief Executive Officer. Mr. Clarke brings over two decades of executive leadership experience in driving company growth, ... |
| 09.01.2025 | Forbion Co-Leads over $410M Series A Financing to Launch Verdiva Bio, a Clinical-Stage Cardiometabolic Company Advancing Next-Generation Therapies | - Co-founded by Khurem Farooq and former members of Aiolos Bio team to develop broad portfolio of oral and injectable treatments for obesity, cardiometabolic disorders, and related complications - Forbion played an instrumental role in the ... |
| 08.01.2025 | Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025 | - Clinical Trial Application for global Phase 3 trials with nizubaglustat in GM1/GM2 gangliosidoses and Niemann-Pick Disease Type C approved in multiple European countries, anticipated to begin in Q2, 2025. These studies are set to be condu... |
| 07.01.2025 | RyCarma Therapeutics Announces New Leadership and Company Name, Introduces Program in Heart Failure | • Formerly ARMGO Pharma, RyCarma builds on 20-year history developing small molecule ryanodine receptor (RyR) allosteric modulators, known as Rycals® • Company advancing lead candidate ARM210 that targets leaky RyRs to correct calcium chann... |
| 06.01.2025 | Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles | - Funding to support the development of pipeline of oral macrocycle drugs, called ‘nCycles,’ focused on validated blockbuster biologic targets - Orbis’ nGen platform systematically explores oral macrocycle design with automated chemistry an... |
| 28.12.2024 | SACHS Associates - 1st BioPharma Obesity Innovation Forum for Science, Drug Development, Technology and Investment | Principal Antoine Boulanger will co-chair the Investor Roundtable at the Sachs Associates 1st BioPharma Obesity innovation Forum. Click here to access the agenda and to learn about registering for this event. |
| 18.12.2024 | Noema Pharma Appoints Volker Knappertz, M.D., as Executive VicePresident of Research &Development | BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, aclinical-stage biotech company targeting debilitating central nervoussystem (CNS) disorders, today announced the appointment of VolkerKnappertz, M.D., as Executive Vice Pr... |
| 17.12.2024 | Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia | - KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the Phase 1 study in healthy volunteers - Initial d... |
| 16.12.2024 | VectorY Strengthens Leadership Team with appointment of Jim Scibetta as new CEO | • Former CEO, Sander van Deventer to become President of R&D • Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package • Expansion of corpo... |
| 12.12.2024 | Forbion Welcomes Gijs van den Brink, MD, PhD. as Operating Partner | • Gijs van den Brink brings over two decades of experience in drug discovery, development, and strategic leadership to Forbion, having previously held senior leadership roles at Roche and GSK • As Operating Partner, his focus will be on sup... |
| 12.12.2024 | Dutch Life Sciences Conference - Leiden | The Dutch Life Sciences Conference takes place on December 12, 2024 at Leiden Bio Science Park. Managing Partner Sander Slootweg will take part in the afternoon panel "The Road to IPO." Click here for more information about ticket... |
| 11.12.2024 | Noema Pharma extends Series B financing round, closing at CHF 130 Million ($147 Million) | - EQT Life Sciences expands the Series B with additional capital, alongside continued support from existing investors, including, Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus, and UPMC Enterprises BA... |
| 11.12.2024 | CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature | • Tumor remissions achieved in First-in-Human Phase 1/2a demonstrate clinical proof-of-concept with the majority of responders experiencing deeper RECIST 1.1 response levels than on their initial anti-PD1/PD-L1 treatment. Long durability an... |
| 09.12.2024 | Citryll Raises Eur 85 Million Series B to Advance Novel Net-Targeting Therapy for Immune-Mediated Inflammatory Disorders | - Financing co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion and Novartis Venture Fund - Lead first-in-class product candidate, monoclonal antibody CIT-013, to be advanced into two Phase 2a studies Oss, Netherlands – 09 Dece... |
| 09.12.2024 | Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform | Cambridge, UK, December 9, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that Johnson & Johnson* has exclusively licensed a novel, undisclosed targe... |
| 02.12.2024 | Forbion, in collaboration with members of the EU Life Sciences ESG Knowledge Project release 2025 questionnaire | Forbion is proud to be a signatory and active member of the EU Life Sciences ESG Knowledge Project, a pioneering initiative supported by Impact House by Grant Thornton. This project unites 22 Life Science investors in developing a coordinat... |
| 02.12.2024 | AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa | December 2, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced that the U.S. ... |
| 22.10.2024 | BioEconomy Policy for Responsible Investments 2024 | - |
| 22.10.2024 | Forbion Policy for Responsible Investments 2024 | - |
| 15.10.2024 | Forbion raises in excess of €2 billion for two new funds | • Forbion’s largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2 billion and Forbion Ventures Fund VII raising €890 million • Assets under management now at €5 billion • Fundraising follows strong performan... |
| 29.09.2024 | World Agri-Tech Innovation Summit | 29 September - 01 October, London The World Agri-Tech Innovation Summit in London is the leading European networking event, uniting over 1000 business leaders and key stakeholders dedicated to driving advancements in climate-resilient, sust... |
| 26.09.2024 | Forbion Head of Impact & ESG named as one of Top 50 Women in Sustainable Finance 2024 | Forbion's Head of Impact and ESG, Silva Dezelan, PhD has been named as one of the Top 50 Women in Sustainable Finance by WIFS The Netherlands. The list highlights female leaders in the Netherlands who are committed to sustainability within ... |
| 18.09.2024 | Nordic Life Science Days - NLS Days 2024 | NLS Days 2024 18 - 19 September, Malmö, Sweden Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the w... |
| 09.09.2024 | Forbion Impact & ESG Report 2023 | This report illustrates how our portfolio companies contributed to science, innovation and the clinical development of new medicines in 2023. It also sets out how they performed across environmental, social and governance (ESG) factors. As ... |
| 27.06.2024 | Forbion Strengthens US Presence, Hiring Biotech Industry Leader and Opening Boston Office | • Josh Brumm, previously CEO of Dyne Therapeutics, appointed as General Partner at Forbion • Brumm to be located at Forbion's new offices in the heart of the Boston (MA) biotech hub, supporting Forbion’s long-standing activities in the US a... |
| 20.06.2024 | Forbion announces first close of its new BioEconomy Fund I: backing biotech-enabled companies aiming to impact the future of our planet | • Forbion, a leading European life sciences venture capital firm, announces the first close of its new fund strategy, Forbion BioEconomy Fund I at €75 million. • Forbion BioEconomy Fund I leverages Forbion’s extensive biotech expertise in h... |
| 02.06.2024 | CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated... | - The results include data from three main study cohorts: In the non-squamous non-small cell lung cancer (NSCLC) cohort, an Objective Response Rate (ORR) for NSCLC of 19.0% (4/21), with 2 Partial Responses (PR) and 2 Complete Responses (CR)... |
| 29.05.2024 | Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases | Naarden, The Netherlands – May 29, 2024 – Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished S... |
| 28.05.2024 | Dyne Therapeutics Announces Closing of Public Offering of Common Stock & Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases... |
| 28.05.2024 | Forbion Announces $1.25 Billion Sale to Johnson & Johnson of Numab Therapeutics Subsidiary, Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis, Marking its Six... | • Forbion announces the sale of Yellow Jersey Therapeutics, a wholly owned subsidiary to be spun off from its portfolio company Numab Therapeutics, an investment of Forbion’s Growth Opportunities Fund I • This is Forbion's sixth consecutive... |
| 23.05.2024 | Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing | - Financing includes participation from new and existing investors - Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the second half of 2027 - Supports ongoing ... |
| 22.05.2024 | Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopa... | NOE-115 has the potential to benefit Vasomotor Symptoms (VMS) during menopause as well as associated clinical challenges including weight gain, daytime fatigue, and cognitive symptoms BASEL, Switzerland, May 22, 2024 – Noema Pharma AG, a cl... |
| 21.05.2024 | Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline | - Financing led by TCGX, including new investment from BVF Partners, Lightspeed Venture Partners (Lightspeed) and Perceptive Advisors - Three first-in-class ADC assets funded through clinical proof of concept London UK, 21 May 2024 – Pheon ... |
| 21.05.2024 | Forbion leads $65 million Series A Financing of Progentos Therapeutics | • Forbion led the Series A financing to support the development of Progentos’ lead program in multiple sclerosis along with additional pipeline programs • Progentos Therapeutics is developing novel small molecules to induce de-novo remyelin... |
| 16.05.2024 | enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors | BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder c... |
| 03.05.2024 | AAVantgarde presents the design of its innovative LUCE-1 trial for USH1B at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit | May 3, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the presentation of... |
| 02.05.2024 | Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana Oncology (Mariana) is to be acquired by Novartis for $1 billion in ... |
| 30.04.2024 | SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab | • SynOx is developing emactuzumab - a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody • Provides flexible loan facility to support additional clinical work and activities to drive its successful registration ... |
| 23.04.2024 | 10th LSX World Congress | General Partner Dirk Kersten will be participating in Day One of the event on the panel "Charting the Course: The 2024 Investment Landscape for European Biotechs" at the 10th LSX World Congress which takes place on 29 -30 April in... |
| 23.04.2024 | AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting | April 23, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the publication ... |
| 23.04.2024 | Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform | DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)-- Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the c... |
| 22.04.2024 | Forbion co-leads $75m Series B Financing in SynOx Therapeutics | •Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures •Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour Dublin, Ireland and Oxford, UK, 22 Apri... |
| 22.04.2024 | Swiss Biotech Day 2024 | The Swiss Biotech Day is a premier biotechnology conference in Europe, attracting professionals from the global life sciences community. In 2024, it will once again provide a platform for networking, engaging discussions, and the exploratio... |
| 17.04.2024 | Anglonordic Life Science Conference | Join Forbion Analysts Anne Marije van Harten, PhD and Alice Vickers, PhD, as they join over 350 delegates from leading and upcoming drug discovery and technology companies from the UK and Nordic regions, and investment firms throughout Euro... |
| 16.04.2024 | 0100 Conference Europe 2024 | Forbion's Head of Impact and ESG, Silva Dezelan, PhD will be a speaker at the 0100 Conference Europe. The conference will take place from 16-18 April in Amsterdam and dives into the heart of The Rise of Impact Investing: Paving the Way for ... |
| 12.04.2024 | Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024 | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases... |
| 03.04.2024 | Prilenia Names Jina Swartz, M.D. Ph.D., as Chief Medical Officer | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases... |
| 20.03.2024 | Forbion Invests in Capstan Therapeutics with participation in $175M Oversubscribed Series B Financing | • Nanna Luneborg, PhD, MBA, General Partner at Forbion to join Capstan Board of Directors • Capstan is the tenth investment from the Forbion Growth Opportunities Fund II Naarden, March 20, 2024 – Forbion, a leading European life sciences ve... |
| 19.03.2024 | Forbion co-leads oversubscribed $157M Series B Financing Round in Engrail Therapeutics | • Proceeds to Support Advancement of Engrail’s Pipeline for Neuropsychiatric and Neurodevelopmental Disorders • Investment marks the ninth from Forbion’s Growth Opportunities II Fund Naarden, The Netherlands – March 19, 2024 – Forbion, a le... |
| 18.03.2024 | Bio-Europe Spring 2024 | Bio-Europe Spring 2024 will take place from 18-20 March, 2024 in Barcelona, Spain. The event connects the global biopharma community to elevate life sciences partnerships. Click here to learn about registering and attending this event. |
| 12.03.2024 | Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative disease... |
| 12.03.2024 | NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD | -- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination (“FDC”) as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD risk equivalents requiring additional lowe... |
| 12.03.2024 | Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients | Major milestone reached in bringing new treatment options to patients and their families Leiden, The Netherlands, March 12, 2024 – Azafaros B.V. today announced the completion of its 12-week Phase 2 clinical study, RAINBOW (Phase 2 RAINBOW ... |
| 29.02.2024 | Forbion co-leads €26 million Seed Financing with launch of Orbis Medicines | • The financing, led by Forbion and Novo Holdings, will support Orbis’ expansion and advancement of its portfolio of next-generation macrocycle drugs called ‘nCycles’ • Orbis’ platform is the first to systematically explore the macrocycle c... |
| 28.02.2024 | 17TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM FOR PARTNERING & INVESTMENT | The 17th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 28th - 29th February 2024 at the Hilton Zurich Airport Hotel. The event will be part of the Sachs Spring Life Sciences Week, which will also incorporate t... |
| 27.02.2024 | Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections | --Company Receives Five-year Exclusivity Extension Through GAIN Act -- SAINT-LOUIS, France & WEILL AM RHEIN, Germany, February 27, 2024 - Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat... |
| 21.02.2024 | NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD) | • Phase 2a study evaluating the safety, tolerability, PK, and PD of Orziloben in IFALD • The study will enrol up to 36 adult subjects at multiple sites in North America • Study strengthens NST’s position as a multi-asset, clinical stage com... |
| 20.02.2024 | Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program | Cambridge, UK, February 20, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful treatments for patients, today announced the appointments of additional di... |
| 14.02.2024 | enGene Announces Oversubscribed $200 Million Private Placement Financing | BOSTON and MONTREAL, Feb. 14, 2024 /CNW/ – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle... |
| 13.02.2024 | NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants | NAARDEN, the Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines f... |
| 01.02.2024 | Bio-Neuroscience | Bio-Neuroscience is the partnering and investment summit for global leaders in CNS neuroscience drug discovery and development and is convened by-invitation. Bio-Neuroscience is a high level, boutique gathering of key thought leaders, innov... |
| 30.01.2024 | Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing | • Round led by new investor Panakes, with participation from all existing investors • Funding will support Phase 2a clinical proof of concept trial in cystic fibrosis for a novel first in class ENaC blocker (ETD001) and pipeline expansion •... |
| 29.01.2024 | ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies | • Phase 1b open label trial confirms safety and tolerability of 120 mg and 200 mg dosing of ARM210 daily in patients with Ryanodine Receptor 1 Related Myopathies • Provides first signs of clinical efficacy improving fatigue and proximal mus... |
| 24.01.2024 | Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders | • First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader • Deep degradation of target protein is achieved in a rapid, sustained, and highly selec... |
| 23.01.2024 | Forbion announces 75 million EUR Series A financing in Calluna Pharma | • Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics to develop novel therapies for inflammatory and fibrotic diseases • Calluna Pharma has a pipeline of selective antibodies targeting immunological diseas... |
| 23.01.2024 | Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™ | • Four posters with baseline data from the natural history (PRONTO) study in patients with GM1 and GM2 gangliosidoses to be presented • Total of eight posters from Azafaros, including study design for the Phase 2 RAINBOW study investigating... |
| 22.01.2024 | Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment | Publication: Progress in Retinal and Eye Research |
| 18.01.2024 | VectorY appoints Khurem Farooq to Board of Directors | · CEO and Co-Founder of Aiolos Bio and previous CEO of Gyroscope Khurem Farooq joins as independent board member |
| 11.01.2024 | Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven disease... |
| 09.01.2024 | Forbion portfolio company Aiolos Bio, Inc. (Aiolos) to be acquired by GSK for up to $1.4 billion | Forbion portfolio company Aiolos Bio, Inc. (Aiolos) is to be acquired by GSK for up to $1.4 billion, including $1 billion upfront and up to $400 million in milestone payments. You can find GSK’s announcement with further details of the acqu... |
Show more
Mentions in press and media 211
| Date | Title | Description |
| 19.09.2026 | Venture Capital Navigates Shifting Tides: Space, AI, and Biotech Secure Billions | Venture capital remains selective. Major funding rounds target critical sectors. Impulse Space secured $308M, valuing orbital logistics at $5.4B. AI innovators Arcee AI, Hang Ten, Noetive, Rune attracted significant capital. Biotech firm Sl... |
| 16.09.2026 | Venture Capital & Startup Funding Roundup, September 16, 2026: Andreessen Horowitz, Index Ventures, M12, Vista Equity & More | Venture capital is not moving evenly today. It is clustering around businesses that control a scarce input, remove an expensive operational bottleneck, or sit close enough to a measurable economic outcome that investors can underwrite somet... |
| 09.09.2026 | Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy | Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer Phase 2 trial of porustobart for colon cancer ... |
| 09.09.2026 | Venture Capital & Startup Funding Roundup, September 9, 2026: Coatue, Andreessen Horowitz, Greylock, Kleiner Perkins, Sequoia & More | Venture capital’s center of gravity today isn’t in one neat category called AI. It is moving toward companies that control high-value workflows: legal work, sales, wealth management, cybersecurity, industrial production and even weather-ris... |
| 10.08.2026 | Expedition Therapeutics Closes $115 Million Series B | SAN FRANCISCO, CA, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B f... |
| 09.08.2026 | Expedition Therapeutics Lands $115M Series B | SAN FRANCISCO, CA, Expedition Therapeutics has announced the closing of an oversubscribed $115 million Series B financing round. >> Click here for more funding data on Expedition Therapeutics >> To export Expedition Therapeutic... |
| 05.08.2026 | Expedition Therapeutics Raises $115M in Series B Funding | Expedition Therapeutics, a San Francisco, CA-based clinical-stage biotechnology platform, raised $115M in Series B financing. The round was led by General Atlantic with participation from RA Capital, Vivo Capital, Sofinnova Investments, Nov... |
| 29.06.2026 | Andera Partners joins the European Life Sciences Coalition (ELSC) with the aim to support the mobilization of capital for life sciences innovation in Europe. | Andera Partners joins the European Life Sciences Coalition (ELSC), alongside Forbion, HealthCap, Novo Holdings, Omega Funds, Sofinnova Partners, Van Lanschot Kempen, VIB, BioInnovation Institute, 4BIO Capital, Cooley and Covington. Launched... |
| 26.06.2026 | RQ Bio Raises $115 Million Series A To Advance Influenza Prevention Antibody Program | RQ Bio announced that it has completed an oversubscribed $115 million Series A financing round. The financing was led by Frazier Life Sciences, with participation from new investors EQT Life Sciences, Forbion, Monograph, and Wellington Mana... |
| 21.06.2026 | Memento Medicines Raises $93 Million Series A For Retinal Disease Therapy | Memento Medicines announced the completion of a $93 million Series A financing round to advance MMT-205, its lead biologic therapy for retinal diseases. The round was co-led by Forbion, RA Capital Management, and Avego BioScience Capital, w... |
| 19.06.2026 | Memento Medicines Raises $93M in Series A Funding | Memento Medicines, Inc., a Boston, MA-based biotech company developing biologic therapies for retinal diseases, raised $93M in Series A funding. The round was led by Forbion, RA Capital Management and Avego BioScience Capital, with particip... |
| 11.05.2026 | CellCentric Secures $220M to Accelerate Myeloma Drug Inobrodib | CellCentric secured $220 million in Series D funding. This capital fuels pivotal clinical trials for inobrodib. Inobrodib is a novel oral p300/CBP inhibitor. It targets relapsed or refractory multiple myeloma. Phase 2 data demonstrated sign... |
| 07.05.2026 | CellCentric: $220 Million Series D Raised To Advance Inobrodib Trials For Multiple Myeloma | CellCentric announced the completion of an oversubscribed $220 million Series D financing to support pivotal clinical trials of inobrodib, the company’s first-in-class oral p300/CBP inhibitor for the treatment of multiple myeloma. The finan... |
| 29.04.2026 | Coultreon Biopharma Raises $125 Million Series A to Advance Oral Autoimmune Therapy | Coultreon Biopharma, a Belgium-based biotechnology company formerly known as Onco3R Therapeutics, has closed an oversubscribed 125 million dollar Series A financing round to advance its immunology pipeline. The round was led by Sofinnova In... |
| 21.03.2026 | Biotech Powerhouse Mestag Therapeutics Secures $40M for Advanced Therapies | Mestag Therapeutics has secured $40 million in new financing. This pushes its total funding past $95 million. The Cambridge-based biotech fuels its Phase 1 STARLYS clinical trial for cancer drug MST-0312. This pivotal trial begins in mid-20... |
| 17.03.2026 | Mestag Therapeutics Raises $40M in Financing | Mestag Therapeutics, a Cambridge, UK-based biotech company harnessing fibroblast immunology to develop treatments for cancer and inflammatory diseases, closed a $40m financing. Backers includwed SV Health Investors, Johnson & Johnson, t... |
| 17.03.2026 | Mestag Therapeutics: $40 Million Raised To Advance Fibroblast Immunology Cancer Therapies Into Clinic | Mestag Therapeutics, a biotech company focused on fibroblast immunology, has announced the closing of a $40 million financing round, bringing its total funding to more than $95 million. The round was backed by SV Health Investors, Johnson &... |
| 15.03.2026 | Tropic Secures $105M: Gene-Edited Crops Reshape Global Food Future | Tropic, a UK AgTech firm, raised $105 million in Series C funding. This capital boosts gene-edited tropical crop expansion. Forbion and Corteva co-led the round. The focus is disease-resistant bananas and climate-resilient rice. Tropic's GE... |
| 15.03.2026 | Tropic: $105 Million Raised To Scale Gene-Edited Tropical Crops And Banana Production | Tropic, a UK-based agricultural biotechnology company developing gene-edited tropical crops, has raised $105 million in an oversubscribed Series C funding round to accelerate global commercial expansion and scale production of its breakthro... |
| 13.03.2026 | UK AgTech startup Tropic secures €91.3 million to bring gene-edited bananas and climate-resilient crops to market | Tropic, a Norwich-based AgTech startup specialising in gene‑edited tropical crops, has announced the close of its oversubscribed €91.3 million ($105 million) Series C financing to accelerate the global scale-up of its banana and rice portfo... |
| 12.03.2026 | Tropic bags $105m to scale gene-edited bananas, deploy TR4 resistant bananas in 2027 | UK-based plant biotech company Tropic has raised a $105 million Series C round to support the rollout of non-browning bananas and bananas with extended shelf-life—innovations it says are opening up the cut fruit market, cutting food waste, ... |
| 26.02.2026 | Slate Medicines Secures $130M to Advance Migraine Prevention | Slate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headach... |
| 24.02.2026 | Slate Medicines: $130 Million Series A Raised To Advance Anti-PACAP Migraine Therapies | Slate Medicines, a privately held biotech company developing next-generation therapeutics for headache disorders, has launched with the close of a $130 million Series A financing and the in-licensing of SLTE-1009, an anti-PACAP monoclonal a... |
| 24.02.2026 | Slate Medicines Raises $130M in Series A Funding | Slate Medicines, a Raleigh, NC-based biotech company, raised $130M in Series A funding. The round was led by RA Capital Management, Forbion, and Foresite Capital with participation from an additional undisclosed biotech investor. In conjunc... |
| 19.02.2026 | Altesa BioSciences: $75 Million Series B Raised For Advancing Vapendavir For Chronic Lung Diseases | Altesa BioSciences, a clinical-stage pharmaceutical company focused on improving outcomes for people with chronic lung diseases, has closed an oversubscribed $75 million Series B financing round to advance development of vapendavir, a first... |
| 19.02.2026 | Altesa BioSciences Raises $75M in Series B Funding | Altesa BioSciences, an Atlanta, GA-based clinical-stage pharmaceutical company raised $75M in Series B funding. The round was led by Forbion, with participation from Sanofi and existing investors, including Medicxi, Pitango, and Atlantic Pa... |
| 11.01.2026 | Corsera Health Secures $80M for Cardiovascular Prevention | Corsera Health secured an $80 million Series A. This capital fuels the company's mission to revolutionize cardiovascular health. It advances preventive RNAi medicines, targeting key drivers: LDL cholesterol and high blood pressure. These on... |
| 08.01.2026 | Corsera Health: $80 Million Series A Raised To Advance Cardiovascular Disease Prediction | Corsera Health announced it raised an oversubscribed $80 million Series A to advance its cardiovascular disease prediction-and-prevention strategy and to fund development of once-annual preventive RNAi medicines targeting the two primary dr... |
| 07.01.2026 | Corsera Health Raises $80M in Series A Financing | Corsera Health, Inc., a Boston, MA-based clinical-stage company leading the future of cardiovascular health through prediction and prevention, raised $80m in Series A financing. The round was led by Forbion and Population Health Partners wi... |
| 06.01.2026 | LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease | Cambridge, UK, 6 January 2026 – LoQus23 Therapeutics Ltd (“LoQus23”), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myo... |
| 01.12.2025 | Protego Biopharma: $130 Million Series B Funding Closed To Advance Pivotal AL Amyloidosis Program | Protego Biopharma has closed an oversubscribed $130 million Series B financing round that will accelerate its first-in-class AL amyloidosis therapeutic program into a pivotal clinical study. The round was led by Novartis Venture Fund and Fo... |
| 16.11.2025 | Gate Bioscience: $65 Million Series B Closed To Advance Oral Molecular Medicines Into Clinical Trials | Gate Bioscience has closed a $65 million oversubscribed Series B financing round to accelerate the advancement of its emerging class of oral small-molecule medicines, known as molecular gates. The round brings the company’s total capital ra... |
| 13.11.2025 | Gate Bioscience Raises $65M in Series B Financing | Gate Bioscience, a Brisbane, California-based biotechnology company developing a new class of small molecule medicines aiming to eliminate disease-causing proteins at their source, closed a $65m Series B financing. The round was led by new ... |
| 10.11.2025 | Forbion Bioeconomy Fund I Reaches €200 Million Hard Cap | Forbion announced that its Forbion BioEconomy Fund I has closed at its hard cap of €200 million, marking one of the most significant dedicated bioeconomy funds in Europe. The fund focuses on biotechnology-driven solutions that support plane... |
| 08.11.2025 | AAVantgarde Secures $141M for Groundbreaking Gene Therapies | AAVantgarde Bio closed a $141 million Series B round. This substantial funding propels gene therapy programs for inherited retinal diseases. Key targets: Stargardt disease and Usher Syndrome Type 1B. Both represent severe conditions with no... |
| 07.11.2025 | AAVantgarde: $141 Million Series B Closed To Advance Clinical Programs For Stargardt Disease And Usher 1B Syndrome | AAVantgarde Bio has closed a $141 million (€122 million) Series B financing to advance its lead clinical programs targeting inherited retinal diseases. The financing round was co-led by Schroders Capital, Atlas Venture, and Forbion, with pa... |
| 06.11.2025 | AAVantgarde Closes $141M Series B Financing | AAVantgarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing therapies for inherited retinal diseases (IRDs), raised $141M in Series B funding. The round was led by Schroders Capital, as well as existing investors ... |
| 06.11.2025 | Braveheart Bio Launches With $185 Million Series A To Advance Treatment For Hypertrophic Cardiomyopathy | Braveheart Bio, a biotechnology company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has launched with $185 million in Series A financing. The investment was led by Andreessen ... |
| 05.11.2025 | Braveheart Bio Raises $185M in Series A Funding | Braveheart Bio, a San Francisco, CA-based clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, raised $185M in Series A financing. Backers included Andreessen Horow... |
| 23.10.2025 | Elevara Medicines Raises $70M in Series A Funding | Elevara Medicines, a London, UK-based clinical-stage biotech developing therapies for rheumatoid arthritis (RA) and chronic inflammatory diseases, closed a $70m Series A financing. The round was co-led by Forbion and Sofinnova Partners, wit... |
| 10.10.2025 | Expedition Therapeutics Raises $165M in Funding | Expedition Therapeutics, a San Francisco, CA-based biotech company developing therapies for novel inflammatory and respiratory diseases, raised $165M in Series A financing. The round was led by Sofinnova Investments and Novo Holdings, with ... |
| 09.10.2025 | Expedition resupplies for phase 2 COPD voyage with $165M series A | Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstruct... |
| 09.10.2025 | Expedition Therapeutics: $165 Million Series A Raised For Advancing DPP1 Inhibitor For COPD | Expedition Therapeutics, a biotechnology company dedicated to developing therapies for novel inflammatory and respiratory diseases, has closed an oversubscribed and upsized Series A financing round, raising $165 million. This financing roun... |
| 27.09.2025 | Sparrow Pharmaceuticals: $95 Million Series B Raised For Advancing Targeted Therapy For Type 2 Diabetes | Sparrow Pharmaceuticals, a company focused on developing therapies for cardiometabolic conditions, recently announced the successful completion of a Series B financing round, raising an impressive $95 million. This significant investment wa... |
| 24.09.2025 | Genomines Secures $45M Series A, Redefining Sustainable Metal Extraction | Genomines, a Paris-based deep tech firm, just raised $45 million in Series A funding. This capital fuels its plant-based metal extraction. The company's phytoextraction technology uses genetically enhanced plants. These hyperaccumulators dr... |
| 24.09.2025 | Sparrow Pharmaceuticals Raises $95M in Series B Financing | Sparrow Pharmaceuticals, a Portland, OR-based cardiometabolic therapeutics company, raised $95M Series B financing. The round was co-led by RA Capital Management and Forbion with participation from existing investors including OrbiMed, Rive... |
| 23.09.2025 | Genomines: $45 Million Series A Raised For Advancing Future Of Metal Extraction | Genomines is a pioneering company that is transforming the future of metal extraction by utilizing innovative, plant-based farming techniques. Recently, the company announced that it has successfully raised an impressive $45 million in its ... |
| 18.09.2025 | Capital meets care: 10 venture capital firms transforming healthcare across Europe | Venture capital remains one of the cornerstones of Europe’s innovation landscape, fuelling the growth of startups across every sector. In our last list, we spotlighted 15 VC firms focused on sustainability, underlining how investors are sha... |
| 18.09.2025 | Genomines raises $45m Series A to mine battery-grade nickel from genetically enhanced plants | Mining is one of those critical components of the global economy that also happens to come with a hefty environmental toll. France-based Genomines is among the companies trying to change that and in the process develop more cost effective a... |
| 17.09.2025 | Genomines Raises $45M in Series A Funding | Genomines, a Paris, France-based metal extraction company focused on plant-based metal farming, raised a $45m Series A funding. The round was led by Engine Ventures and Forbion BioEconomy, with participation from DeepTech & Climate Fond... |
| 16.09.2025 | CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development | Experienced executives, Clinton Musil, Sujata Rao, MD, Heike Krupka, PhD, and Andrea Goddard join CatalYm to broaden and accelerate clinical programs into late-stage development Munich, Germany and San Francisco, USA, September 15, 2025 – C... |
| 05.09.2025 | China's Hengrui Rises After Granting Braveheart Bio Heart Drug Rights in Up to USD1.1 Billion Deal | (Yicai) Sept. 5 -- Shares of Hengrui Pharmaceuticals rose after the drugmaker granted US' Braveheart Bio the exclusive global rights outside of China to an innovative heart drug in a deal worth as much as USD1.1 billion, the Chinese firm's ... |
| 30.07.2025 | MapLight: $372.5 Million Series D Funding Raised For Developing Therapeutics For Central Nervous System | MapLight Therapeutics announced a $372.5 million oversubscribed Series D financing, co-led by Forbion and Goldman Sachs Alternatives, with participation from Sanofi, T. Rowe Price, Avego BioScience, and existing investors like Novo Holdings... |
| 28.07.2025 | MapLight Therapeutics Raises $372.5M in Series D Funding | MapLight Therapeutics, a Redwood City, CA-based clinical-stage biopharmaceutical company, raised $372.5M in Series D financing. The round was led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional... |
| 16.07.2025 | Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment | Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the successful achievement of a discovery researc... |
| 30.06.2025 | Forbion Announces Fifth Exit from Forbion Growth Opportunities Fund II with the Sale of Capstan Therapeutics to AbbVie for USD 2.1 Billion | • Capstan sale ranks as the largest ever payment for an early-stage private biotech company by upfront consideration value and is Forbion’s seventh consecutive >$1B exit. • Capstan’s in vivo CAR-T platform offers a first-in-class approac... |
| 10.06.2025 | Mosanna Therapeutics: A Breath of Fresh Air in Sleep Apnea Treatment | In the realm of healthcare, innovation often emerges from the shadows of necessity. Mosanna Therapeutics, a biotech company based in Redwood City, California, is stepping into the spotlight with a groundbreaking approach to treating obstruc... |
| 10.06.2025 | Mosanna Therapeutics raises USD 80 million to advance sleep apnea nasal spray | Mosanna Therapeutics, the clinical-stage biotech company headquartered in Basel, is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at nighttime that helps restore the body’s natural ai... |
| 09.06.2025 | EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray | EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray Mon, Jun 09, 2025 16:15 CET Report this content Series A Funding will be used to advance Mosanna’s nasal spray therapy ... |
| 09.06.2025 | Forbion co-leads $80 Million Series A Financing in Mosanna Therapeutics to Advance Novel Nighttime Nasal Spray for Obstructive Sleep Apnea | Naarden, The Netherlands – June 9, 2025 – Forbion, a leading venture capital firm with deep biotech expertise in Europe and the US announces that it has co-led an $80 Million Series A financing in Mosanna Therapeutics, a biotech company ret... |
| 20.05.2025 | Cellcentric: $120 Million Raised For Treating Multiple Myeloma | CellCentric, a clinical-stage biotechnology company developing inobrodib (a first in class oral cancer drug to treat specific cancers, notably multiple myeloma) announced the completion of a $120 million Series C funding round. The funding ... |
| 19.05.2025 | Azafaros: €132 Million Secured To Develop Treatments For Lysosomal Storage Disorders | Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announced the completion of an oversubscribed €132 million Series B fi... |
| 19.05.2025 | CellCentric Raises $120M In Series C Funding | CellCentric, a Cambridge, UK-based clinical-stage biotechnology company, raised $120M in Series C funding. The round was led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital, as well as Bri... |
| 19.05.2025 | Forbion co-leads $120 million investment in CellCentric to advance inobrodib for treating multiple myeloma | • Funding to support late stage development of a novel oral p300/CBP inhibitor, inobrodib for the treatment of multiple myeloma • As part of its global team expansion, the company opened a new office just outside Boston in Burlington, MA • ... |
| 14.05.2025 | The Rise of Biotech: A New Era of Innovation and Investment | In the world of biotechnology, the stakes are high and the rewards can be life-changing. Recent funding rounds reveal a landscape ripe with potential. Companies like Azafaros and Eligo Bioscience are leading the charge, armed with innovativ... |
| 13.05.2025 | Forbion co-leads € 132M Series B Oversubscribed Financing in Azafaros to Advance Phase 3 Clinical programs of innovative therapies in lysosomal storage disorders | • Financing round led by Jeito Capital and co-led by Forbion Growth, with participation from Seroba, Pictet Group and other existing investors • Proceeds to fund two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick di... |
| 13.05.2025 | Azafaros Raises €132M in Series B Financing | Azafaros, a Leiden, the Netherlands-based clinical-stage company developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, raised €132M in Series B funding. The round was led... |
| 29.04.2025 | German fashiontech eeden secures €18M Series A to scale textile recycling technology | Münster-based eeden, a German startup specializing in chemical textile recycling, has closed an €18M Series A round. The investment was led by Forbion's BioEconomy Fund, with participation from Henkel Ventures, NRW.Venture, and existing inv... |
| 26.04.2025 | Granite Bio: A New Force in Immunology with $100 Million Backing | Granite Bio has burst onto the scene, armed with $100 million in funding. This clinical-stage immunology company is not just another player; it’s a potential game-changer. With a focus on autoimmune diseases, Granite Bio is targeting the ro... |
| 25.04.2025 | Granite Bio: Immunology Company Debuts With $100 Million In Funding | Granite Bio, a clinical-stage immunology company, announced it has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund and a $70 millio... |
| 25.04.2025 | Granite Bio debuts with $100 million to tackle autoimmune diseases | Granite Bio is a biotechnology company developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions. Its pipeline comprises two lead candidates. GRT-001 depletes pro-infl... |
| 27.01.2025 | Forbion BioEconomy Fund I surpasses €150 million target, raising €164.5 million with strong institutional LP support | • Forbion’s BioEconomy Fund I has raised €164.5 million to date, exceeding its €150 million target in just over a year, since launching in November 2023. • Institutional investors, include KfW Capital, Novo Holdings, Rentenbank, Aurae Impac... |
| 12.01.2025 | European Tech Landscape: A Surge of Innovation and Investment | The European tech scene is buzzing. A recent wave of funding, acquisitions, and innovative breakthroughs paints a vibrant picture of the continent's entrepreneurial spirit. This week alone, over 40 tech funding deals topped €1.3 billion. Th... |
| 10.01.2025 | Numab Therapeutics: A Financial Surge in the Fight Against Cancer | In the world of biotechnology, where innovation meets investment, Numab Therapeutics has made headlines with its recent financial maneuvering. The Swiss company, known for its pioneering work in multi-specific antibodies, has successfully c... |
| 10.01.2025 | Numab Therapeutics raises $55M for antibody-based immunotherapies | Biotech Numab Therapeutics has raised $55 million, bringing its Series C fundraise to $197 million. Numab is a clinical-stage company developing multi-specific antibody-based immunotherapies for inflammation and cancer. Its developed a repr... |
| 10.01.2025 | Verdiva Bio launches with $411M Series A raise for next-gen oral and injectable treatments for obesity | Pharmatech company Verdiva Bio launched this week with an eye-watering $411 million Series A. Focused on developing innovative therapies for obesity and other cardiometabolic disorders, Verdiva Bio is creating next-generation oral and injec... |
| 09.01.2025 | Numab raises additional CHF50 million | In 2024 Numab caused a stir with the acquisition of the biotech’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion. Numab’s immuno-oncology therapeutic NM26 entered the clinic and the company started a collabo... |
| 09.01.2025 | Forbion Co-Leads over $410M Series A Financing to Launch Verdiva Bio, a Clinical-Stage Cardiometabolic Company Advancing Next-Generation Therapies | - Co-founded by Khurem Farooq and former members of Aiolos Bio team to develop broad portfolio of oral and injectable treatments for obesity, cardiometabolic disorders, and related complications - Forbion played an instrumental role in the ... |
| 06.01.2025 | Orbis Medicines: Oral Macrocycle Drug Discovery Company Raises €90 Million (Series A) | Orbis Medicines – a leader in oral macrocycle drug discovery – announced today the closing of a €90 million Series A funding round, bringing the total amount raised by the company to €116 million. The funding round will support the developm... |
| 11.12.2024 | Noema Pharma extends Series B funding to CHF 130 million | EQT Life Sciences’ LSP 7 fund has invested in Noema Pharma. The clinical-stage biotech company headquartered in Basel is developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The Series... |
| 11.12.2024 | EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million | EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million Wed, Dec 11, 2024 09:30 CET Report this content Proceeds will be used to enable key late-stage clinical trial readouts for asset... |
| 10.12.2024 | Citryll's €85 Million Boost: A New Dawn for Inflammatory Disease Treatment | In the world of biotech, funding is the lifeblood. Recently, Dutch startup Citryll secured a significant €85 million in Series B funding. This financial windfall is not just a number; it represents hope for countless patients battling immun... |
| 09.12.2024 | Oss-based Citryll secures €85 million Series B funding to advance NET-targeting therapy | Dutch startup Citryll, a biotech innovator in immune-mediated inflammatory diseases, has raised €85 million in a Series B funding round. The financing was co-led by Johnson & Johnson Innovation (through its corporate venture capital org... |
| 09.12.2024 | Citryll Raises EUR 85M in Series B Funding | Citryll, an Oss, The Netherlands-based biotech company developing a new approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), raised €85M in Series B funding. The round was led by Joh... |
| 16.10.2024 | Gate.io Launches Cryptocurrency Venture Capital Fund | Gate Ventures Capital, the venture capital arm of global cryptocurrency exchange Gate.io, launched a Cayman Islands domiciled, closed-ended private fund. The venture capital fund initially closed with investments in the digital assets and w... |
| 16.10.2024 | Forbion Raises Over €2 Billion For Two Funds | Forbion, a Naarden, The Netherland-based life sciences venture capital firm, raised over €2 billion ($2.2 billion) across two funds. Forbion Growth Opportunities Fund III and Forbion Ventures Fund VII will each invest in approximately 15 po... |
| 15.10.2024 | Forbion raises in excess of €2 billion for two new funds | • Forbion’s largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2 billion and Forbion Ventures Fund VII raising €890 million • Assets under management now at €5 billion • Fundraising follows strong performan... |
| 11.10.2024 | Investment Climate Podcast: Giuseppe Scionti of NovaMeat | In this podcast series, Alex Shandrovsky interviews investors about benchmarks for funding alt proteins in 2024 and uncovers the investment playbooks of successful climate tech CEOs and leading VCs. Podcast Host Alex Shandrovksy is a strate... |
| 02.10.2024 | LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease | Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy ... |
| 19.09.2024 | Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative dise... |
| 12.09.2024 | Novameat's €17.4M Funding: A Leap into the Future of Plant-Based Meat | In the bustling heart of Barcelona, a culinary revolution is brewing. Novameat, a pioneering plant-based meat startup, has secured €17.4 million in a Series A funding round. This investment, led by Sofinnova Partners and Forbion via its Bio... |
| 12.09.2024 | Novameat raises $19.2m to expand next-gen plant-based meat texturizing tech: ‘We have a clear path to profitability’ | Barcelona-based plant-based meat startup Novameat has raised a €17.4m ($19.2 million) series A round. Sofinnova and Forbion BioEconomy led the round, supported by existing investors Praesidium, Unovis Asset Management and Rubio Impact Ventu... |
| 12.09.2024 | Novameat Closes $19.2M Series A Round, Revamps Plant-Based Shredded Beef with Better Texture | 5 Mins Read Spain’s Novameat has attracted €17.4M in a Series A funding round to expand its plant-based meat range based on MicroForce technology, starting with a revamped shredded beef offering. Catalan food tech startup Novameat has recei... |
| 12.09.2024 | Novameat Secures €17.4M in Oversubscribed Round, Launches Improved Shredded Plant-Based Beef | Barcelona’s Novameat, a B2B company specializing in different cuts of plant-based chicken, beef, and turkey, announces it has raised €17.4 million in an oversubscribed Series A round led by Sofinnova Partners and Forbion via its BioEconomy ... |
| 11.09.2024 | SOLASTA Bio: A New Dawn for Sustainable Agriculture | In the world of agriculture, the battle against pests is relentless. Farmers wield traditional insecticides like swords, but these weapons are losing their edge. Resistance is rising, and the environmental toll is becoming too heavy to bear... |
| 11.09.2024 | Solasta Bio: A Green Revolution in Crop Protection | In a world grappling with the dual challenges of food security and environmental sustainability, Solasta Bio emerges as a beacon of hope. This Glasgow-based agri-biotech company has recently secured $14 million in Series A funding, a signif... |
| 11.09.2024 | Solasta Bio Closes $14M Series A Funding | Solasta Bio, a Glasgow, Scotland, UK-based agri-biotech company specialising in green insecticides, raised $14M in Series A funding. The round, which brought the total raised to date to $19m, was led by Forbion, FMC Ventures and Corteva Cat... |
| 11.09.2024 | SOLASATA Bio raises $14m, plans to commercialize peptide-based biopesticides in ‘half the time’ it takes for synthetics | UK-based ag biotech startup SOLASTA Bio has closed a $14 million oversubscribed Series A round, bringing its total funding to $19 million. Forbion (via its Bioeconomy fund), FMC Ventures, and Corteva (through its recently launched Corteva C... |
| 11.09.2024 | Glasgow-based Solasta Bio raises $14M Series A for green insecticides | Solasta Bio, an agri-biotech company providing green insecticides, has completed a $14M Series A funding round to accelerate the development of its peptide-based, nature-inspired bioinsecticides – the first of their kind to be developed wor... |
| 28.07.2024 | CatalYm's $150 Million Bet on Cancer Resistance: A New Dawn in Immunotherapy | In the relentless battle against cancer, CatalYm has emerged as a beacon of hope. The Munich-based company recently secured $150 million in Series D funding, a significant leap forward in its mission to combat cancer therapy resistance. Thi... |
Show more